Respiratory


Severe COPD Phase III Case Study

Integrated Approach to Pulmonary Studies

Research into respiratory disease continues to have a high profile due to unmet needs and the large patient populations.

Asthma is one of the top 15 most important disorders in terms of global years lived with disability and affecting over 300 million people of all ages in all parts of the world. It causes about 250,000 deaths each year. Prevalence shows an increase year by year, especially in developing countries and children.

COPD is expected to be the 3rd leading cause of death worldwide and by 2020 and the 5th leading cause of years lost through early mortality or disability. Cystic fibrosis is affecting over 70,000 people worldwide. This is about 1 of 2500 live births in Caucasians. The Lung is affected in 90% of patients surviving the neonatal period and end-stage lung disease is the principal cause of death.

Allergic rhinitis and conjunctivitis affects over 400 million people around the world, which to a large extent remain underdiagnosed and undertreated. Children are especially affected.

Idiopathic Pulmonary Fibrosis has approximately 30,000–35,000 new patients diagnosed each year. 

Factsheet: ICON offers therapeutic experience combined with operational and technical capabilities across in trial delivery ThumbnailFactsheet: ICON offers therapeutic experience combined with operational and technical capabilities across in trial deliveryDownload Factsheet

Global team of respiratory experts
Our global team of over 400 scientific and medical experts are committed to anticipating and overcoming the challenges to your drug development pipeline. Our experts provide insight in respiratory clinical trials for drugs, devices, and drug-device combinations.

Partner of choice in Respiratory trials
Driving milestone success, ensuring high quality data and delivering on budget are key to how we work for you. Our deliverables are given stretch targets and monitored by senior management to maximise on results. We work with companies that range in size from large pharmaceutical companies and smaller biotech companies to niche providers. We also have partner status with a number of the world's top ten pharmaceutical companies.

Market leader in adaptive design
Having supported over 200 adaptive design trials globally across all phases of clinical development, we have more experience of adaptive trials in respiratory studies than any other CRO in the industry. We are leaders in design and implementation of adaptive clinical trials,.

Compelling offering

We can offer you extensive global experience in program consultancy and multi-service studies, along with full-service clinical development program ownership.

Allergies and respiratory profiles
Our experts collaborate with research groups, key opinion leaders, and site networks to develop our allergic rhinitis and respiratory profile and to ensure you get the best advice on your trial.

Applied innovation 
ICON provides a full range of clinical development services to deliver a more tailored service for your needs. This includes FIRECREST our site management and training platform, Medical Imaging, eCOA, and Adaptive Trial Design.

Experience you can trust
We have managed 24 studies over the last 3 years with a focus on clinical delivery. These studies enrolled over 8,000 patients from about 800 sites globally. We are currently completing two Global COPD studies involving over 280 sites and 2,500 patients.

Expert leadership
ICON has over 400 experienced respiratory team members across Europe, North America, Latin America and Asia Pacific to help you deliver your clinical trial.  Our experts include pulmonologists and members with medical backgrounds.